Order Total (1 Item Items):
Shipping Destination:
Tulum Oner Lazonick William (17 results)
Skip to main search results
Search filters
Product Type
- All Product Types
- Books (17)
- Magazines & Periodicals (No further results match this refinement)
- Comics (No further results match this refinement)
- Sheet Music (No further results match this refinement)
- Art, Prints & Posters (No further results match this refinement)
- Photographs (No further results match this refinement)
- Maps (No further results match this refinement)
- Manuscripts & Paper Collectibles (No further results match this refinement)
Condition Learn more
- New (13)
- As New, Fine or Near Fine (4)
- Very Good or Good (No further results match this refinement)
- Fair or Poor (No further results match this refinement)
- As Described (No further results match this refinement)
Binding
Collectible Attributes
- First Edition (No further results match this refinement)
- Signed (No further results match this refinement)
- Dust Jacket (No further results match this refinement)
- Seller-Supplied Images (7)
- Not Print on Demand (14)
Language (1)
Free Shipping
Seller Location
Seller Rating
-
From Financialisation to Innovation in Uk Big Pharma : Astrazeneca and Glaxosmithkline
Book 4 of 8: Elements in Reinventing CapitalismLanguage: English
Published by Cambridge University Press, 2022
ISBN 10: 1009278169 ISBN 13: 9781009278164
Condition: New.
-
From Financialisation to Innovation in Uk Big Pharma : Astrazeneca and Glaxosmithkline
Book 4 of 8: Elements in Reinventing CapitalismLanguage: English
Published by Cambridge University Press, 2022
ISBN 10: 1009278169 ISBN 13: 9781009278164
Condition: As New. Unread book in perfect condition.
-
Innovation versus Financialization in the US Pharmaceutical Industry
Language: English
Published by Cambridge University Press, GB, 2025
ISBN 10: 1009707981 ISBN 13: 9781009707985
Seller: Rarewaves.com USA, London, LONDO, United Kingdom
Seller rating 5 out of 5 stars
Paperback. Condition: New. Mandated by the Inflation Reduction Act of 2022, the US government is negotiating with pharmaceutical companies over the 'maximum fair price' of ten drugs widely used by Medicare patients. The pharmaceutical companies contend that a 'fair' price is a 'value-based price' that enables their shareholders to capture the value the drug creates for society and warn that lowering drug prices will reduce investments in new drugs. This Element responds to these arguments by showing that pharmaceutical companies (a) should have their drug prices regulated, given scale economies in supplying drugs and price inelasticity of drug demand; (b) use their profits from unregulated drug prices to distribute cash dividends and stock buybacks to shareholders; (c) do not typically rely upon investment by shareholders to fund drug innovation; and (d) benefit from 'collective and cumulative learning' in foundational and translational research that is antecedent and external to their investments in clinical research.
-
Innovation versus Financialization in the US Pharmaceutical Industry
Language: English
Published by Cambridge University Press, GB, 2025
ISBN 10: 1009707981 ISBN 13: 9781009707985
Paperback. Condition: New. Mandated by the Inflation Reduction Act of 2022, the US government is negotiating with pharmaceutical companies over the 'maximum fair price' of ten drugs widely used by Medicare patients. The pharmaceutical companies contend that a 'fair' price is a 'value-based price' that enables their shareholders to capture the value the drug creates for society and warn that lowering drug prices will reduce investments in new drugs. This Element responds to these arguments by showing that pharmaceutical companies (a) should have their drug prices regulated, given scale economies in supplying drugs and price inelasticity of drug demand; (b) use their profits from unregulated drug prices to distribute cash dividends and stock buybacks to shareholders; (c) do not typically rely upon investment by shareholders to fund drug innovation; and (d) benefit from 'collective and cumulative learning' in foundational and translational research that is antecedent and external to their investments in clinical research.
-
From Financialisation to Innovation in Uk Big Pharma : Astrazeneca and Glaxosmithkline
Book 4 of 8: Elements in Reinventing CapitalismLanguage: English
Published by Cambridge University Press, 2022
ISBN 10: 1009278169 ISBN 13: 9781009278164
Seller: GreatBookPricesUK, Woodford Green, United Kingdom
Seller rating 5 out of 5 stars
Condition: New.
-
Innovation Versus Financialization In The Us Pharmaceutical Industry
Language: English
Published by Cambridge University Press, 2025
ISBN 10: 1009707981 ISBN 13: 9781009707985
Paperback. Condition: Brand New. 96 pages. 6.00x0.22x9.00 inches. In Stock.
-
From Financialisation to Innovation in Uk Big Pharma : Astrazeneca and Glaxosmithkline
Book 4 of 8: Elements in Reinventing CapitalismLanguage: English
Published by Cambridge University Press, 2022
ISBN 10: 1009278169 ISBN 13: 9781009278164
Seller: GreatBookPricesUK, Woodford Green, United Kingdom
Seller rating 5 out of 5 stars
Condition: As New. Unread book in perfect condition.
-
Innovation versus Financialization in the US Pharmaceutical Industry
Language: English
Published by Cambridge University Press, GB, 2025
ISBN 10: 1009707981 ISBN 13: 9781009707985
Paperback. Condition: New. Mandated by the Inflation Reduction Act of 2022, the US government is negotiating with pharmaceutical companies over the 'maximum fair price' of ten drugs widely used by Medicare patients. The pharmaceutical companies contend that a 'fair' price is a 'value-based price' that enables their shareholders to capture the value the drug creates for society and warn that lowering drug prices will reduce investments in new drugs. This Element responds to these arguments by showing that pharmaceutical companies (a) should have their drug prices regulated, given scale economies in supplying drugs and price inelasticity of drug demand; (b) use their profits from unregulated drug prices to distribute cash dividends and stock buybacks to shareholders; (c) do not typically rely upon investment by shareholders to fund drug innovation; and (d) benefit from 'collective and cumulative learning' in foundational and translational research that is antecedent and external to their investments in clinical research.
-
Innovation Versus Financialization In The Us Pharmaceutical Industry
Language: English
Published by Cambridge University Press, 2025
ISBN 10: 100970799X ISBN 13: 9781009707992
Condition: As New. Unread book in perfect condition.
-
Innovation Versus Financialization In The Us Pharmaceutical Industry
Language: English
Published by Cambridge University Press, 2025
ISBN 10: 100970799X ISBN 13: 9781009707992
Condition: New.
-
Innovation Versus Financialization In The Us Pharmaceutical Industry
Language: English
Published by Cambridge University Press, 2025
ISBN 10: 100970799X ISBN 13: 9781009707992
Seller: GreatBookPricesUK, Woodford Green, United Kingdom
Seller rating 5 out of 5 stars
Condition: New.
-
Innovation Versus Financialization In The Us Pharmaceutical Industry
Language: English
Published by Cambridge University Press, 2025
ISBN 10: 100970799X ISBN 13: 9781009707992
Seller: GreatBookPricesUK, Woodford Green, United Kingdom
Seller rating 5 out of 5 stars
Condition: As New. Unread book in perfect condition.
-
Innovation versus Financialization in the US Pharmaceutical Industry
Language: English
Published by Cambridge University Press, GB, 2025
ISBN 10: 1009707981 ISBN 13: 9781009707985
Paperback. Condition: New. Mandated by the Inflation Reduction Act of 2022, the US government is negotiating with pharmaceutical companies over the 'maximum fair price' of ten drugs widely used by Medicare patients. The pharmaceutical companies contend that a 'fair' price is a 'value-based price' that enables their shareholders to capture the value the drug creates for society and warn that lowering drug prices will reduce investments in new drugs. This Element responds to these arguments by showing that pharmaceutical companies (a) should have their drug prices regulated, given scale economies in supplying drugs and price inelasticity of drug demand; (b) use their profits from unregulated drug prices to distribute cash dividends and stock buybacks to shareholders; (c) do not typically rely upon investment by shareholders to fund drug innovation; and (d) benefit from 'collective and cumulative learning' in foundational and translational research that is antecedent and external to their investments in clinical research.
-
Innovation Versus Financialization In The Us Pharmaceutical Industry
Language: English
Published by Cambridge University Press, 2025
ISBN 10: 100970799X ISBN 13: 9781009707992
Hardcover. Condition: Brand New. 96 pages. 6.00x0.25x9.00 inches. In Stock.
-
Innovation Versus Financialization In The Us Pharmaceutical Industry
Language: English
Published by Cambridge University Press, 2025
ISBN 10: 1009707981 ISBN 13: 9781009707985
Paperback. Condition: Brand New. In Stock. This item is printed on demand.
-
Condition: New. Dieser Artikel ist ein Print on Demand Artikel und wird nach Ihrer Bestellung fuer Sie gedruckt. Inhaltsverzeichnis1. Introduction 2. Innovation and Competition in the Global Pharmaceutical Industry 3. The Innovation-Financialisation Tension in the Global Pharmaceutical Industry 4. AstraZeneca 5. GlaxoSmithKline 6. Explaining t.
-
Innovation Versus Financialization In The Us Pharmaceutical Industry
Language: English
Published by Cambridge University Press, 2025
ISBN 10: 100970799X ISBN 13: 9781009707992
Hardcover. Condition: Brand New. 96 pages. 6.00x0.25x9.00 inches. In Stock. This item is printed on demand.
